全文获取类型
收费全文 | 182768篇 |
免费 | 17583篇 |
国内免费 | 11752篇 |
专业分类
耳鼻咽喉 | 1642篇 |
儿科学 | 1907篇 |
妇产科学 | 2435篇 |
基础医学 | 21909篇 |
口腔科学 | 3267篇 |
临床医学 | 23960篇 |
内科学 | 26765篇 |
皮肤病学 | 2212篇 |
神经病学 | 9533篇 |
特种医学 | 6488篇 |
外国民族医学 | 98篇 |
外科学 | 18684篇 |
综合类 | 29747篇 |
现状与发展 | 39篇 |
一般理论 | 22篇 |
预防医学 | 12270篇 |
眼科学 | 4762篇 |
药学 | 19760篇 |
191篇 | |
中国医学 | 10986篇 |
肿瘤学 | 15426篇 |
出版年
2024年 | 727篇 |
2023年 | 2997篇 |
2022年 | 7841篇 |
2021年 | 9817篇 |
2020年 | 7405篇 |
2019年 | 6325篇 |
2018年 | 6663篇 |
2017年 | 6115篇 |
2016年 | 5710篇 |
2015年 | 8784篇 |
2014年 | 10633篇 |
2013年 | 9824篇 |
2012年 | 14308篇 |
2011年 | 15434篇 |
2010年 | 9854篇 |
2009年 | 7583篇 |
2008年 | 10075篇 |
2007年 | 9538篇 |
2006年 | 9152篇 |
2005年 | 8878篇 |
2004年 | 5689篇 |
2003年 | 5159篇 |
2002年 | 4271篇 |
2001年 | 3603篇 |
2000年 | 3796篇 |
1999年 | 3859篇 |
1998年 | 2290篇 |
1997年 | 2341篇 |
1996年 | 1783篇 |
1995年 | 1732篇 |
1994年 | 1513篇 |
1993年 | 906篇 |
1992年 | 1279篇 |
1991年 | 1115篇 |
1990年 | 895篇 |
1989年 | 844篇 |
1988年 | 761篇 |
1987年 | 623篇 |
1986年 | 458篇 |
1985年 | 396篇 |
1984年 | 190篇 |
1983年 | 162篇 |
1982年 | 93篇 |
1981年 | 123篇 |
1980年 | 79篇 |
1979年 | 108篇 |
1978年 | 52篇 |
1977年 | 51篇 |
1976年 | 42篇 |
1974年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography 下载免费PDF全文
23.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
24.
25.
To evaluate the anthropometric indexes in subjects with varicocele compared to controls and the incidence of varicocele in different body mass index (BMI) groups for the purpose of exploring the association between varicocele and anthropometric indexes. A comprehensive literature search was conducted by using PubMed, MEDLINE, EMBASE databases and Cochrane Library up to February 2019. A systematic review and meta‐analysis was conducted by STATA, and Newcastle–Ottawa Scale was utilised for assessing risk of bias. Ultimately, 13 articles containing seven case–control studies and six cross‐sectional studies with 1,385,630 subjects were involved in our study. Pooled results demonstrated that varicocele patients had a lower BMI (WMD = ?0.77, 95% CI = ?1.03 to ?0.51) and a higher height than nonvaricocele participants, especially in grade 3 varicocele patients. Subgroup analyses showed that normal BMI individuals had a higher risk of varicocele than obese or overweight individuals and a lower risk than underweight individuals. In conclusion, this study indicates that varicocele patients have a lower BMI and a higher height than nonvaricocele participants. Moreover, men with excess bodyweight have a lower incidence of varicocele compared to normal weight or underweight people. That is to say, high BMI and adiposity protect against varicocele and high BMI is associated with a decreased risk of varicocele. 相似文献
26.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
27.
28.
29.
30.